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Summary Pentoxifylline (PTX) has been shown to increase radiation damage to tumours and to decrease late
radiation-induced injury to normal tissues. This tumour radiation sensitisation results from increased oxygen
supply via improved tumour perfusion. We propose that the improved perfusion results from decreased
viscous resistance and/or geometric resistance. The decreased flow resistance may be accompanied by a
reduction in microvascular pressure (MVP). Since MVP is approximately equal to the interstitial fluid pressure
(IFP), PTX should lead to a decrease in IFP. To test this hypothesis, we measured P02, laser Doppler flow
(RBC flux) and IFP in FSaII murine tumours at two doses (PTX at 25 and 100 mg per kg body weight) which
sensitise this tumour to X-irradiation. We found that 25mg kg' PTX was ineffective, but 100mg kg-' PTX
was effective in increasing the P02 of this tumour. PTX at 100 mg kg-l (i.p.) increased median P02 from 5 to
7 mmHg (P<0.05) within 2h, and decreased the fraction of P02 values <5 mmHg from 65% to 45%
(P<0.05). In support of our hypothesis, we found that with this dose of PTX, RBC flux in the tumour centre
increased significantly (n = 6, P<0.05) prior to an -40% decrease (n = 13, P<0.05) in tumour interstitial
fluid pressure (TIFP), without changes in mean arterial blood pressure (MABP). In conclusion, a single i.p.
administration of PTX at 100 mg kg-' can increase oxygen availability in the tumour due to temporarily
increased RBC flux in the tumour centre, where pretreatment flow is relatively low, and thus ameliorate
hypoxia in tumour microregions. Second, PTX can lower the elevated TIFP without lowering the MABP.
The original studies of Dion et al. (1989, 1990) demonstrated
that in the post-irradiation period multiple injections of pen-
toxifylline (PTX) can decrease late radiation-induced injury
to normal tissue as a result of an improved blood supply.
PTX has also been shown to be a radiation sensitiser (Lee &
Cho, 1991; Lee et al., 1992a, 1993). Single or multiple doses
of 100 mg kg-' PTX can increase the radiation-induced
tumour growth delay as well as local control of FSaII murine
tumours. Recently, Song et al. (1992) found an increased
P02 20-50 min following PTX treatment (5 or 50 mg kg-' in
a single dose) in FSaII tumours. The increased PO2 in
tumours results from reduced oxygen consumption (Gullino,
1975; Vaupel et al., 1987) and/or increased oxygen
availability through modifications in tumour blood flow
(TBF) (Coleman, 1988). While there are no direct
measurements of in vivo oxygen consumption following PTX
treatment, Lee et al. (1993) have shown that single injection
of PTX does not increase the RBC flux in the periphery of
FSaII tumours using the laser Doppler surface probe.
Therefore, there are ambiguous results upon single admini-
stration of various dosages of PTX. In this study we focused
on single injection of PTX. We measured intra-tumour P02
in control and PTX (25 and 100 mg kg-')-treated groups. We
also measured the RBC flux in the periphery and centre of
FSaII tumours with a standard surface probe as well as a
needle probe using laser Doppler flowmetry to determine if
the increased oxygenation with PTX was due to a greater
oxygen availability. Furthermore, similar to our recent study
with nicotinamide (Lee et al., 1992b), we hypothesised that if
PTX can decrease resistance to blood flow it could also lower
tumour hypertension. Therefore, we measured tumour inter-
stitial fluid pressure (TIFP) using the wick-in-needle method
(WIN).
Materials and methods
Animals and tumour cells
Female C3Hf/Sed mice, 8-10 weeks of age, were used.
Animals were maintained under specific pathogen-free condi-
tions on a sterile standard laboratory diet. This study was
conducted under Massachusetts General Hospital Animal
Care Committee Regulations for animal welfare. The FSaII
(fourth generation) tumours were transplanted sub-
cutaneously into the right thigh of mice (Lee et al., 1992b).
Experiments for the measurement of physiological
parameters such as RBC flux, P02, TIFP and mean arterial
blood pressure (MABP) were carried out when tumour
volume reached -250mm3.
Pentoxifylline (PTX) treatment
Pentoxifylline (PTX), a derivative of methyl xanthine, 3,7-
dimethyl-1-(5-oxyhexyl) xanthine, was dissolved in sterile
saline before the experiments. The mice were given an i.p.
injection of two different dosages of PTX (25 or
100 mg kg-') in a volume of 0.01 ml per g of body weight.
Dezube et al. (1990) have calculated the conversion factor
between mice and humans for PTX using Freireich's quan-
titative interspecies comparison (Freireich et al., 1966), i.e. a
dosage of 100 mg kg-' PTX in mice is equivalent to a dosage
of 8 mg kg-' in humans. From their phase I trials for
escalating PTX, cancer patients received an - 1,600 mg dose
at maximal tolerance dose during the first cycle of PTX
(Dezube et al., 1990); this is equivalent to '-25 mg kg' for
patients of 65 kg body weight or -300 mg kg -in mice.
However, this dose was close to LDso530) of our mouse strain.
Therefore, we used 100mgkg'I for the high end of PTX
dosage in this study.
Anaesthesia
The mice were anaesthetised with ketamine (90 mg kg-') and
xylazine (9 mg kg-') via an i.m. route and placed on a water
heating pad to keep the body (rectal) temperature at 37.5°C.
In sham controls both tumour and body temperature were
measured. Average tumour temperature was
-34°C when
the body temperature was maintained at 37.5C.
Measurement ofintra-tumour P02
Intra-tumour P02 was measured with a commercially
available 27 gauge needle-type electrode (General Diamond,
Ann Arbor, MI, USA). Briefly, a membranised recessed
cathode (sensor electrode: diameter = 25 jAm) is insulated
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with glass and mounted in a 27 gauge needle. The sensor
electrode is gold plated on platinum wire and protected by an
oxygen-permeable membrane (oxygen sensitivity is
- 7 x 10-'2 amp mmHg-' 02). The temperature of the P02
calibration solutions was maintained at --34°C using a cali-
bration cell mounted in a water bath (General Diamond),
and the electrodes were calibrated by immersing them in a
series of isotonic saline solution saturated with four different
known oxygen levels (0%, 5%, 10% and 20% oxygen). In
each tumour 25-50 measurements were made, and the data
were recorded by a Mac Lab/4 analogue-to-digital system
(ADInstruments, Castle Hill, New South Wales, Australia)
linked to a Macintosh computer. P02 was measured at
20-50min following the injection of 25mgkg-' PTX. Fol-
lowing the observation that RBC flux was not modified with
a PTX dose of 25 mg kg-', but was significantly increased in
less than Omin and remained elevated for a period of at
least 90 min at a dose of 100 mg kg-', we decided to measure
P02 over a period of 60-90 min following the injection of
PTX. It is known that electrode signal shifts with time;
therefore, we measured P02 over an - 30 min period, and we
then compared the calibration values before and after
measurements of P02 to confirm whether the measured
oxygen values were acceptable. The P02 values were dis-
carded when the calibration values shifted by more than 2%
in 30 min (Lee et al., 1990).
Measurements ofrelative TBF (laser Dopplerflow; LDF)
Relative TBF (RBC flux) was measured using the Laserflow
Blood Perfusion Monitor 403A (TSI, St. Paul, MN, USA).
For the application of a laser Doppler surface probe, a probe
was placed on the tumour surface after the skin was removed
(Lee et al., 1991). In a different group of animals, a small
hole was made in the tumour using a 23 gauge needle and a
0.8-mm-diameter laser Doppler needle probe was inserted in
the tumour centre, and then slightly withdrawn to ensure
that there was no compression of the tumour under the
probe tip. The electrical signal of flow, velocity and volume
from the laser Doppler systems were digitally processed using
the Mac Lab/4 analogue-to-digital system (ADInstruments)
linked to a Macintosh computer with output voltage ranging
from 0V to 2.5 V. RBC flux was monitored for a period of
90 min following the injection of PTX. In addition, the zero-
flow signal was measured at the end of the experiments by
sacrificing the animals with an overdosage of anaesthesia; the
biological zero-flow signal was well above electrical zero
(output signals were usually between --,25 mV and - 150 mV
in dead animals).
Measurement ofmean arterial bloodpressure (MABP) and
tumour interstitialfluidpressure (TIFP)
The right carotid artery was cannulated with a PE-10
polyethylene catheter, as previously described (Lee et al.,
1992b). TIFP was measured with the WIN technique (Fadnes
et al., 1977; Boucher et al., 1991; Lee et al., 1992b). In brief,
a 23 gauge needle with a side-hole -~- 3 mm from the tip was
filled with five nylon surgical sutures (6-0 Ethilon; Ethicon,
Somerville, NJ, USA). The needle was connected to a pres-
sure transducer by PE-50 polyethylene tubing filled with
sterile heparinised (70 unitsml-') saline. Before pressure
measurements in each animal, the calibration of the pressure
transducer set-up was verified by applying pressures of 0, 5,
15 and 30 cm of saline. TIFP was measured continuously in
the centre of tumours with one needle before and for 4 h
following the injection of PTX.
Data analysis
All values except P02 are shown as mean ± standard error
(s.e.) of each group and time points for the parametric
statistic. Percentage changes were determined individually for
each mouse, based on pretreatment values, and then
averaged. Significant differences within a group before and
after PTX treatment were evaluated using a paired t-test, and
between treatment groups with an unpaired t-test. Tumour
P02 histograms were tested for significant difference in
median values for two independent samples using a U-
test.
Results
PTX at a dose of 25 mg kg-' did not improve tumour
oxygenation significantly, although Po2 values below
5 mmHg decreased from 65 to 56% (data not shown). How-
ever, the PTX dose of 100mgkg-' increased median P02
from 5 to 7 mmHg (P<0.05). Intra-tumour P02 values below
5mmHg significantly decreased (P<0.05) from 65 to 45%
(Figure la and b). The improved tumour oxygenation at a
PTX dose of 100mgkg-' was associated with a statistically
significant increase in RBC flux in the centre of tumours
(n = 6, P<0.05). The increase in RBC flux was significant at
5 and 10min post treatment, and remained at that level
(- 1.3-fold) for at least 90 min (Figure 2). In a few animals,
RBC flux was monitored up to 4 h, and it remained elevated
for 4 h (data not shown). However, when the standard sur-
face probe was used, RBC flux in the tumour periphery was
not modified (data not shown). No differences in the RBC
flux in the periphery or centre of tumours were found at a
PTX dose of 25 mgkg' as well as in the saline-treated
animals.
Figure 3 shows changes in MABP and TIFP as a function
of time after an i.p. injection of 100 mgkg-' PTX (n = 13).
MABP was - 75 mmHg after the anaesthesia, and it slightly
fluctuated without any significant reduction in MABP during
4 h post injection. TIFP significantly decreased (P<0.05) by
- 30% at 1 h after an i.p. injection of 100 mg kg-' PTX, and
further decreased to reach a minimum of -55% of the
control value by 2 h, and then remained at that level for up
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Figure 1 Frequency distribution of P02 in FSaII tumours
(n = 8-10, mean tumour volume - 250mm3). a, Saline-treated
control group. b, 100mgkg-' PTX (i.p.) group. Intra-tumour
P02 measurements were done between 60 and 90min after the
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for 6 h, and it periphery and centre supports the concept that PTX is more
Llue (data not effective in regions with impaired blood flow. This is prob-
me course of ably the case for FSaII tumours, since P02 values decrease
[at of increase from the tumour periphery to the tumour centre (data not
1L muscle was shown).t It is also in agreement with previous reports show-
iot altered by ing that PTX mainly works in the presence of impaired
vascularity such as in intermittent claudication or other mic-
rocirculatory diseases (Ambrus et al., 1979; Muller, 1981;
Dettelbach & Aviado, 1985; Ward & Clissold, 1987; Kishi et
al., 1988).
Our data support the hypothesis that the increased P02
evaluate the with PTX at 100 mg kg-' is due to a greater oxygen
irs with PTX availability. Note that median P02 values increased by a
it a PTX dose factor of - 1.4 after PTX treatment, whereas RBC flux in
ntly increased the centre of tumours increased by a factor of - 1.3. One
)2 <5 mmHg possible explanation is that the increase in LDF (RBC flux)
of PTX at ratio underestimates the increase in TBF, mainly because of
lative tumour the zero-flow signal produced by tissue micromotions and
ver, the PTX Brownian motion of blood cells (Wheatley et al., 1993).
D parameters. Therefore, it is reasonable to conclude that there was no
the tumour difference in the response between RBC flux and intra-
tumour P02.
Tumour blood flow (TBF) is proportional to arterial minus
venous pressure (AP) and inversely proportional to flow
resistance (Jain, 1988). Since PTX did not modify MABP, it
is quite likely that the principal effect of PTX was on flow
resistance. PTX has been shown to decrease WBC and RBC
rigidity (Muller, 1981; Dettelbach & Aviado, 1985; Ward &
Clissold, 1987), reduce platelet aggregation (Ambrus et al.,
1979) as well as reduce fibrinogen levels (Jarret et al., 1977).
By exerting a rheological effect on blood cells PTX could
reduce viscous resistance and thus increase tumour per-
fusion.
Reduced TBF during tumour growth has been attributed
in part to vessel collapse. Some investigators have postulated
that the vascular collapse results from higher hydrostatic
pressure in the interstitial space compared with the microvas- 100 cular space (Paskins-Hurlburt et al., 1982; Wiig, 1982). TBF
increased rapidly and reached plateau levels 10 min after the
injection of PTX (Figure 2), whereas TIFP was still decreas-
ing up to 120 min following the injection of PTX (Figure 3).
)TRBC
flux in Since the decrease in TIFP occurred subsequent to the in-
sTX
treatment crease in TBF, the TIFP modification cannot explain the
sured by laser improvement in TBF.
Tumour centre Elevated TIFP is pathophysiological characteristic of
C flux (n = 6, rodent as well as human solid tumours (Jain, 1987; Boucher
inistration of et al., 1990, 1991; Roh et al., 1991; Gutmann et al., 1992; Lee
et al., 1992b; Less et al., 1992). It is also believed to be a
major obstacle to the delivery of macromolecules (Jain, 1987,
1989; Jain & Baxter, 1988). Therefore, the second goal of this
1.5 study was to lower TIFP using PTX. TIFP is governed
predominantly by the local MVP (Boucher & Jain, 1992) and
F the hydraulic conductivity of the interstitial compartment
.C (Baxter & Jain, 1989).$ MVP can be increased (or decreased)
0, by increasing (or decreasing) the arterial pressure and/or by
s 1.0 ' increasing (decreasing) the venous resistance in tumours. We
have recently shown that angiotensin II raises MABP, which
leads to an increase in AP across the tumour vasculature,
co and hence an increase in relative TBF (Zlotecki et al., 1993).
a: Some of this arterial pressure is also transmitted to the
W0.5 tumour microvessels, raising their MVP and hence TIFP
40 270 (Zlotecki et al., 1993). We also recently demonstrated that
nicotinamide decreases both MABP and TIFP; therefore, a
Figure 3 Changes in MABP (0) and TIFP (0) in FSaII
tumours as a function of time after an i.p. injection of
100mgkg-' PTX (n=4-13, bars=s.e.m. tumour volume
- 250 mm3). MABP and TIFP were measured simultaneously 4 h
after PTX treatment.
tNote that P02 does not decrease toward the centre in all tumours.
Indeed, we found that in several human tumour xenografts (e.g.
LS174T, HGL-9, HP-56, SCC21, etc.) in nude mice P02 does not
decrease from the periphery to the centre (J. Lee & R.K. Jain,
unpublished data).
$Although there are no data in the literature on the effect of PTX on
hydraulic conductivity, we cannot exclude the possibility that the
decrease in TIFP is caused by an increase in the hydraulic conduc-
tivity of the interstitial space.
*In preliminary studies we found that TIFP also decreased in larger
tumours (between -350mm3 and -600 mm3).
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fraction of the TIFP drop could be attributed to the MABP
decrease (Lee et al., 1992b). Furthermore, the decrease in
flow resistance caused by nicotinamide can also lead to in-
creased TBF and decreased TIFP (Lee et al., 1992b). PTX,
on the other hand, has no effect on MABP. How then can
TBF go up and TIFP go down? We hypothesise that PTX
lowers the viscous resistance to blood flow, and hence in-
creases TBF. The decrease in viscous resistance also leads to
a lower MVP, which results in lower TIFP.
Song et al. (1992) reported that the increase in P02 in
FSaII tumours after 5 mg kg-' PTX varied between - 2 and
7 mmHg, peaking at 20-50 min post treatment, and then
declining to the original value. In the present study, following
a PTX dose of 25 mg kg-' tumour oxygenation was not
improved at 20-50min post treatment (data not shown).
One possible reason for the discrepancy between the two
studies is as follows. In the work by Song et al. (1992), P02
modifications induced by PTX were measured continuously
at a single position in the tumour. A single measurement per
tumour may not represent an increased oxygenation through-
out the tumour. Therefore, our study supports the
mechanism that radiosensitisation in vivo by PTX may be due
to increased oxygen availability in tumours, and thus
enhanced tumour oxygenation.
In conclusion, the increase in tumour oxygenation and
relative TBF (RBC flux) by PTX at 100 mg kg-' was
significant; however, we failed to show the same effect at a
dosage of 25 mg kg-' PTX. PTX at 100 mg kg-' can increase
oxygen availability in the tumour as a result of temporary
increases in RBC flux in the tumour centre, and thus
ameliorate hypoxia in tumour microregions. Also, PTX at
100 mg kg' can significantly lower the elevated TIFP with-
out lowering the MABP.
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sure; LDF, laser Doppler flow: WIN, wick-in-needle.
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